Clinical Trial Update: XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy [Phase 3]

View source ↗

Summary

Phase 3 trial of XEN496 (ezogabine) in children with KCNQ2 developmental and epileptic encephalopathy was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Developmental and Epileptic Encephalopathy
• Epilepsy
• Kcnq2-related Epilepsy

Drugs mentioned

• XEN496 (ezogabine)

Snippet

Sponsor: Xenon Pharmaceuticals Inc. | Conditions: Epilepsy, Epilepsy in Children | Phase 3 | Status: TERMINATED | Results posted: 2024-08-23